Landgren Ola, Tilly Hervé
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-7236, USA.
Leuk Lymphoma. 2008;49 Suppl 1:35-42. doi: 10.1080/10428190802311425.
Non-follicular indolent subtypes of non-Hodgkin lymphoma (NHL), which include chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL) and marginal zone lymphomas (MZL), are a diverse group of disorders with different presenting features, behaviour patterns and treatment outcomes. Current knowledge of these subtypes is largely based on retrospective analyses. A precise diagnosis can be difficult to achieve, and specific diagnostic criteria are needed to more precisely define some of the rarer indolent tumors, such as nodal and splenic MZLs. Although some subtypes of NHL have a prolonged indolent course, with a good prognosis (e.g. SLL), others (e.g. nodal and splenic MZLs) can rapidly evolve into more aggressive subtypes. In asymptomatic patients, treatment may be deferred until the disease progresses and the patient becomes symptomatic. Universally accepted therapeutic guidelines do not exist, however, and carefully designed, prospective clinical studies are needed to further assess optimal therapeutic approaches for these indolent NHLs.
非霍奇金淋巴瘤(NHL)的非滤泡性惰性亚型,包括慢性淋巴细胞白血病、小淋巴细胞淋巴瘤(SLL)和边缘区淋巴瘤(MZL),是一组多样的疾病,具有不同的临床表现、行为模式和治疗结果。目前对这些亚型的认识主要基于回顾性分析。精确诊断可能难以实现,需要特定的诊断标准来更精确地定义一些较为罕见的惰性肿瘤,如淋巴结和脾脏MZL。虽然某些NHL亚型病程呈惰性且预后良好(如SLL),但其他亚型(如淋巴结和脾脏MZL)可能迅速演变为更具侵袭性的亚型。对于无症状患者,治疗可推迟至疾病进展且患者出现症状时。然而,目前尚无普遍接受的治疗指南,需要精心设计的前瞻性临床研究来进一步评估这些惰性NHL的最佳治疗方法。